Agios Pharmaceuticals: Early Aqvesme Traction and REMS-Driven Uptake Support Robust Mitapivat Growth and Buy Rating

H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Agios Pharma today and set a price target of $65.00.

Emily Bodnar has given his Buy rating due to a combination of factors that highlight the strength of Agios Pharma’s commercial execution and growth outlook. The early launch of Aqvesme (mitapivat) is showing robust traction, with a notable number of prescriptions written in roughly the first month despite the added complexity of a REMS program and the fact that many prescribers are new to mitapivat, underscoring strong underlying demand and favorable physician reception.

Moreover, management’s guidance on the addressable thalassemia population, combined with expectations for accelerating revenue recognition as more physicians and patients complete REMS and payers formalize coverage, supports a meaningful sales ramp from 2Q–4Q 2026. The firm’s revenue assumptions for Aqvesme, informed by a comparable launch trajectory seen with Filspari under a similar REMS construct, along with ongoing Pyrukynd sales, create a credible path to growing mitapivat revenues, which in turn underpins the positive view on valuation and justifies maintaining a Buy recommendation on AGIO.

Bodnar covers the Healthcare sector, focusing on stocks such as Agios Pharma, NovoCure, and Acrivon Therapeutics, Inc.. According to TipRanks, Bodnar has an average return of 11.0% and a 32.19% success rate on recommended stocks.